Pfizer has raised its full-year adjusted earnings per share (EPS) guidance to a range of USD 2.90–3.10, up from its prior outlook of USD 2.80–3.00, following strong second-quarter results that beat market expectations.

The company reported adjusted Q2 EPS of USD 0.78, surpassing the consensus estimate by around 36%. Total revenue for the quarter reached USD 14.65 billion, up approximately 10 per cent year-on-year, aided in part by favourable currency movements amounting to roughly USD 22 million. Demand remained robust for key products including Vyndaqel, Eliquis, Comirnaty (COVID-19 vaccine), Paxlovid, and its cancer drug Padcev.

Despite challenges such as political pressure to reduce drug pricing and potential 15 per cent U.S. tariffs on imports, Pfizer confirmed its full-year revenue outlook of USD 61–64 billion. The forecast incorporates a one-time regulatory charge of USD 0.20 per share linked to a licensing agreement with China’s 3SBio for an experimental cancer medicine.

CEO Albert Bourla highlighted the company’s strong U.S. manufacturing footprint across ten sites, enabling Pfizer to mitigate potential tariff disruptions. The firm expects significant savings from its cost-cutting initiatives—targeting approximately USD 4.5 billion by end-2025 and USD 7.2 billion by 2027—as a key driver of improved margins.

The earnings beat sent Pfizer shares higher by around 3–5 per cent in pre-market trading, reaffirming investor confidence in its margin-focused strategy amid evolving global headwinds.